Related Articles

• Treatment with combined dabrafenib and trametinib in BRAF^V600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation
• Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
• Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors

Article Page

Abstract

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with a significant negative impact on the quality of life of patients.

Methods: We conducted a systematic review to assess current treatment for HS, with a special focus on therapies approved or used in Brazil. We used the PICO framework to improve the research process. The systematic review was reported in line with the PRISMA statement checklist. The search was conducted with clinical questions on two global databases (PubMed (MEDLINE) and Google Scholar) and three databases especially selected to retrieve Brazilian outcomes (BVS, SCIELO and REDALYC).

Results: Overall, 4640 articles were screened, 182 articles were analysed and 70 were used in a thematic qualitative analysis. Of these, 12 articles were from Brazil. The evidencebased literature was largely limited to case reports, case series, observational studies and expert opinion. Topical therapy, lifestyle interventions and oral antibiotics appeared as effective measures for mild HS. However, moderate-to-severe HS remains refractory to conventional treatments.

Conclusion: Some biologic agents, such as adalimumab, infliximab, ustekinumab and secukinumab, have been shown to be effective in the management of moderate-to-severe HS that failed conventional treatment and demonstrated a good tolerability and safety profile.

Keywords: biologic agents, chronic inflammatory skin disease, hidradenitis suppurativa, secukinumab.

Citation: Rivitti-Machado MC, Ferreira Magalhães R, Souto da Silva R, Duarte GV, Bosnich FZS, Tunala RG, Forestiero FJ. Therapies for hidradenitis suppurativa: a systematic review with a focus on Brazil. Drugs Context. 2022;11:2021-9-6. https://doi.org/10.7573/dic.2021-9-6

Contributions: All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: MCR-M reports no conflicts of interest other than as a speaker for Abbvie, Novartis, Janssen and advisory board for Abbvie, Novartis. GVD reports no conflicts of interest other than as a speaker, composing educational material, scientific support and advisory board from Janssen, Pfizer, Leo Pharma, Ucb, Novartis, Boeringer-Ingelhein, Bayer, Abbvie, Biolab. RFM reports no conflicts of interest other than as a speaker and/or advisory board from Janssen, Pfizer, Leo Pharma, Novartis, Boehringer-Ingelhein, Abbvie. RSdS report no conflicts of interest. FZSB, RGT and FJF are employees of Novartis Biociências SA. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/11/dic.2021-9-6-COI.pdf

Acknowledgements: Writing and editorial assistance was provided by Content Ed Net (Madrid, Spain) with funding from Novartis. The authors thank Miss Danika Silveira (Novartis) for her important contribution to the development of the study.

Funding declaration: The study was funded by Novartis.

Copyright: Copyright © 2022 Rivitti-Machado MC, Ferreira Magalhães R, Souto da Silva R, Duarte GV, Bosnich FZS, Tunala RG, Forestiero FJ. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2022 Rivitti-Machado MC, Ferreira Magalhães R, Souto da Silva R, Duarte GV, Bosnich FZS, Tunala RG, Forestiero FJ. https://doi.org/10.7573/dic.2021-9-6. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/therapies-for-hidradenitis-suppurativa-a-systematic-review-with-a-focus-on-brazil

Correspondence: Francisco José Forestiero, Professor Vicente Rao Avenue, 90 – Zip code 04636-000 – São Paulo, SP – Brazil. Email: francisco.forestiero@novartis.com

Provenance: Submitted; externally peer reviewed.

Submitted: 24 September 2021; Accepted: 18 November 2021; Publication date: 19 January 2022.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF